中南大学李乾斌

Central South University|

+

个人信息

李乾斌

教授

教授博士生导师

入职时间：2010-04-22

所在单位：湘雅药学院

职务：博士生导师

学历：博士研究生毕业

办公地点：湖南省长沙市岳麓区桐梓坡路172号中南大学湘雅药学院

在职信息：在职

同专业博导

同专业硕导

论文成果

当前位置: 中文主页 >> 论文成果

Li, Q., Xu, W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents 2005, 5(1): 53-63.
Xu, W., Li, Q. Progress in the development of aminopeptidase N (APN/CD13) inhibitors. Curr. Med. Chem. Anticancer Agents 2005, 5(3): 281-301.
Li, Q., Fang, H., Xu, W. Novel 3-galloylamido-N'-substituted-2,6 -piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(10): 2935-2938.
Li, Q., Al-Ayoubi, A., Guo, T., Zheng, H., Sarkar, A., Nguyen, T., Eblen, S.T., Grant, S., Kellogg, G.E., Zhang, S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19(21): 6042-6046.
Li, Q., Fang, H., Wang, X., Hu, L., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I. Eur. J. Med. Chem. 2009, 44(12): 4819-4825.
Li, Q., Fang, H., Wang, X., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II. Eur. J. Med. Chem. 2010, 45(4): 1618-1626.
Li, Q., Wu, J., Zheng, H., Liu, K., Guo, T.L., Liu, Y., Eblen, S.T., Grant, S., Zhang, S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine -2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. Med. Chem. Lett. 2010, 20(15): 4526-4530.
Li, Q., Fang, H., Wang, X., Hu, G., Wang, Q., Xu, W. Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Bioorg. Med. Chem. Lett. 2012, 22(2): 850-853.
Lv, M., Chen, Z., Hu, G., Li, Q. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov. Today 2015, 20(3): 332-346.
Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., Li, Q. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Med. Chem. 2015, 7(3): 269-289.
Yu, Z., Wang, Z., Wu, X., Hu, G., Li, Q. "One-Pot" Synthesis of 1-Phenyl-1H-benzimidazole Derivatives Facilitated by Fe. Chin. J. Org. Chem. 2016, 36(7): 1672-1676.
Hu, L., Wang, Z., Yi, R., Yi, H., Xiao, S., Chen, Z., Hu, G., Li, Q. Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases. Curr. Med. Chem. 2017, 24(29): 3203-3215.
Xiao, S., Li, Q., Hu, L., Yu, Z., Yang, J., Chang, Q., Chen, Z., Hu, G. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go? Mini Rev. Med. Chem. 2019, 19(18): 1544-1557.
Yu, Z., Chen, Z., Su, Q., Ye, S., Yuan, H., Kuai, M., Lv, M., Tu, Z., Yang, X., Liu, R., Hu, G., Li, Q. Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives. Bioorg. Med. Chem. 2019, 27(6): 944-954.
Huang, P., Le, X., Huang, F., Yang, J., Yang, H., Ma, J., Hu, G., Li, Q., Chen, Z. Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. J. Med. Chem. 2020, 63(9): 4685-4700.
Hu, L., Zhao, R., Liu, Q., Li, Q. New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. Front. Physiol. 2020, 11: 1081.
Hu, L., Li, L., Chang, Q., Fu, S., Qin, J., Chen, Z., Li, X., Liu, Q., Hu, G., Li, Q. Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. J. Med. Chem. 2020, 63(19): 11215-11234.

共17条 1/1

首页上页下页尾页